Journal Article

DZNE-2026-01040

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Amyloid, p-tau, neurofilament light, and α-synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease.

Rizzo, M. ; Teunissen, C. E. ; Zetterberg, H. ; Blennow, K. ; Kollmorgen, G. ; Krüger, R. ; Fernandes, S. B. G. ; Aarsland, D. ; Borejko, O. ; Hu, M. ; Chokoshvili, D. ; Vijverberg, J. E. G. B. ; Lemstra, A. W. ; Tijms, B. M. ; Petzold, G. C.DZNE* ; Brockmann, K.DZNE* ; Gasser, T.DZNE* ; Frisoni, G. B. ; Hort, J. ; Nedelska, Z. ; Hopøy, A.-C. ; Fladby, T. ; Jessen, F.DZNE* ; Düzel, E.DZNE* ; Spottke, A.DZNE* ; Höglinger, G. U.DZNE* ; Mutel, S. ; Chevalier, C. ; Krishnan, R. ; Visser, P. J. ; Vos, S. J. B. ; consortium, E. (Collaboration Author)

2026
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/dad2.70498

Abstract: Mounting evidence suggests overlapping pathology across Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's disease (PD), yet its extent and clinical implications remain unclear.Cerebrospinal fluid (CSF) amyloid beta (Aβ)42/40, phosphorylated tau 181 (p-tau181), neurofilament light chain (NfL), and total α-synuclein were centrally measured using fully-automated Elecsys immunoassays in 347 participants (European Platform for Neurodegenerative Diseases [EPND] cohort) and compared between groups. Associations of amyloid and tau positivity with cognitive and motor function were evaluated.Compared to controls, amyloid and tau levels were abnormal in DLB, but not in PD. Amyloid and tau positivity in DLB were associated with worse global cognitive outcomes, but not with motor performance. NfL levels were elevated across diseases, and total α-synuclein levels were associated with tau positivity.AD pathology is observed in DLB, and related to worse cognition, but it is less observed in PD. CSF NfL captures non-disease-specific processes, whereas CSF total α-synuclein likely reflects CSF tau positivity. Results can help patient management in clinical practice and trials.

Keyword(s): Alzheimer's disease ; Elecsys ; Parkinson's disease ; amyloid ; cerebrospinal fluid ; cognition ; dementia with Lewy bodies ; longitudinal ; motor function ; neurodegenerative diseases ; neurofilament light ; risk factors ; tau ; α‐synuclein

---

Contributing Institute(s):

1. Vascular Neurology (AG Petzold)
2. Parkinson Genetics (AG Gasser)
3. Clinical Alzheimer’s Disease Research (AG Jessen)
4. Clinical Neurophysiology and Memory (AG Düzel)
5. Clinical Research Platform (CRP) (AG Spottke)
6. Clinical Research Platform (CRP) (Clinical Research Platform (CRP))
7. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; DEAL Wiley ; DOAJ Seal ; Emerging Sources Citation Index ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Web of Science Core Collection

---